参考文献
［1］ Murphy SP，Ibrahim NE，Januzzi JL.Heart failure with reduced ejection fraction：A review［J］.JAMA，2020，324：488-504.
［2］ Yancy CW，Jessup M，Bozkurt B，et al.2017 ACC／AHA／HFSA focused update of the 2013 ACCF／AHA guideline for the management of heart failure：A report of the American College of Cardiology／American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America［J］.J Am Coll Cardiol，2017，70：776-803.
［3］ Yancy CW，Januzzi JL Jr，Allen LA，et al.2017 ACC expert consensus decision pathway for optimization of heart failure treatment：Answers to 10 pivotal issues about heart failure with reduced ejection fraction：A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways［J］.J Am Coll Cardiol，2018，71：201-230.
［4］ Seferovic PM，Ponikowski P，Anker SD，et al.Clinical practice update on heart failure 2019：Pharmacotherapy，procedures，devices and patient management.An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology［J］.Eur J Heart Fail，2019，21：1169-1186.
［5］ Michael E Nassif，Mikhail Kosiborod.Effects of sodium glucose cotransporter type 2 inhibitors on heart failure［J］.Diabetes Obes Metab，2019，21 Suppl 2：19-23.
［6］ Abraham WT，Lindenfeld J，Ponikowski P.Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction，with and without type 2 diabetes［J］.Eur Heart J，2021，42：700-710.
［7］ Vaduganathan M，Claggett BL，Jhund PS，et al.Estimating lifetime benefits of comprehensive diseasemodifying pharmacological therapies in patients with heart failure with reduced ejection fraction：A comparative analysis of three randomised controlled trials［J］.Lancet，2020，396：121-128.
［8］ Perez DM.Targeting adrenergic receptors in metabolic therapies for heart failure［J］.Int J Mol Sci，2021，22：5783.
［9］ Nochioka K，Sakata Y，Shimokawa H.Combination therapy of renin angiotensin system inhibitors and betablockers in patients with heart failure［J］.Adv Exp Med Biol，2018，1067：17-30.
［10］ Joseph P，Swedberg K，Leong DP，et al.The evolution of beta-blockers in coronary artery disease and heart failure（Part 1／5）［J］.J Am Coll Cardiol，2019，74：672-682.
［11］ Elgendy IY，Mahtta D，Pepine CJ.Medical therapy for heart failure caused by ischemic heart disease［J］.Circ Res，2019，124：1520-1535.
［12］ Di Palo KE，Barone NJ.Hypertension and heart failure：Prevention，targets，and treatment［J］.Heart Fail Clin，2020，16：99-106.
［13］ Pathak A，Mrabeti S.Beta-blockade for patients with hypertension，ischemic heart disease or heart failure：Where are we now？［J］.Vasc Health Risk Manag，2021，17：337-348.
［14］ Raby K，Rocco M，Oparil S，et al.Heart failure primary prevention：What does SPRINT add？recent advances in hypertension［J］.Hypertension，2021，77：1804-1814.
［15］ Wintrich J，Kindermann I，Ukena C，et al.Therapeutic approaches in heart failure with preserved ejection fraction：Past，present，and future［J］.Clin Res Cardiol，2020，109（9）：1079-1098.(https://www.daowen.com)
［16］ Zheng SL，Chan FT，Nabeebaccus AA，et al.Drug treatment effects on outcomes in heart failure with preserved ejection fraction：A systematic review and meta-analysis［J］.Heart，2018，104：407-415.
［17］ Gupta AK，Tomasoni D，Sidhu K，et al.Evidence-based management of acute heart failure［J］.Can J Cardiol，2021，37：621-631.
［18］ Antohi EL，Ambrosy AP，Collins SP，et al.Therapeutic advances in the management of acute decompensated heart failure［J］.Am J Ther，2019，26：e222-e233.
［19］ Mitter SS，Pinney SP.Advances in the management of acute decompensated heart failure［J］.Med North Am，2020，104：601-614.
［20］ Hohendanner F，Heinzel FR，Blaschke F，et al.Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure［J］.Heart Fail Rev，2018，23：27-36.
［21］ Patel RB，Vaduganathan M，Shah SJ，et al.Atrial fibrillation in heart failure with preserved ejection fraction：Insights into mechanisms and therapeutics［J］.Pharmacol Ther，2017，176：32-39.
［22］ Kosmala W.Heart failure with preserved ejection fraction and atrial fibrillation：How to fight allied enemies［J］.J Am Coll Cardiol，2020，76：1065-1067.
［23］ Javed S，Koniari I，Fox D，et al.Catheter ablation for atrial fibrillation in heart failure：Untying the Gordian knot［J］.J Geriatr Cardiol，2021，18：297-306.
［24］ Wang CC，Hess CN，Hiatt WR，et al.Clinical update：Cardiovascular disease in diabetes mellitus：Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms，management，and clinical considerations［J］.Circulation，2016，133：2459-2502.
［25］ Mc Hugh K，DeVore AD，Wu J，et al.Heart failure with preserved ejection fraction and diabetes：JACCstateof-the-art review［J］.J Am Coll Cardiol，2019，73：602-611.
［26］ Lehrke M，Marx N.Diabetes mellitus and heart failure［J］.Am J Cardiol，2017，120（1S）：S37-S47.
［27］ Kenny HC，Abe ED.Heart failure in type 2 diabetes mellitus：Impact of glucose lowering agents，heart failure therapies and novel therapeutic strategies［J］.Circ Res，2019，124：121-141.
［28］ Marx N，Floege J.Heart failure in advanced chronic kidney disease：Treatment rationale［J］.Herz，2021，46：217-220.
［29］ Ronco C，Bellasi A，Di Lullo L.Implication of acute kidney injury in heart failure［J］.Heart Fail Clin，2019，15：463-476.